Brachytherapy for Peripheral Retinal Capillary Haemangioblastoma in von Hippel-Lindau Disease

Abstract

Aim To report our experience with ¹⁰⁶ruthenium-brachytherapy of peripheral capillary haemangioblastomas in patients with von Hippel-Lindau disease.

Design Retrospective case series.

Methods A total of 53 haemangioblastomas, treated with ¹⁰⁶ruthenium-brachytherapy, were included in our study. The applied radiation dose, visual outcome, angioma activity, need for vitreoretinal surgery and incidence of secondary complications such as macular oedema, secondary glaucoma, vitreous haemorrhage, and epiretinal gliosis were assessed.

Results All treated eyes could be preserved. In 11 patients (20.8%), single brachytherapy did not achieve complete inactivation of the tumour. 31% developed macular oedema postoperatively. Tractional retinal detachment developed in 23.8%, and epiretinal gliosis was observed in 2.4% of patients. Vitreoretinal surgery was necessary in 50% of all treated eyes. At the end of the follow-up, 40.5% of all treated eyes achieved visual acuity (VA) of 0.6 or better, and one third reached a VA of less than 0.1. Mean irradiation dose to the tumour apex was 144 Gy. Higher apex doses correlated with better tumour control of irradiated haemanigoblastomas and lower complication rates.

Conclusions Brachytherapy of peripheral retinal capillary haemangioblastomas is an effective treatment modality. Higher irradiation doses seem to lead to more successful treatment.

Key words

von Hippel-Lindau - VHL - retinal capillary hemangioblastoma - brachytherapy - ruthenium

Publikationsverlauf

Eingereicht: 15. Februar 2021

Angenommen: 18. Mai 2021

Artikel online veröffentlicht:
10. August 2021

• References/Literatur

• 1 Klingler JH, Gläsker S, Bausch B. et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst 2020; 36: 2537-2552
• 2 Kreusel KM. Ophthalmological manifestations in VHL and NF 1: pathological and diagnostic implication. Fam Cancer 2005; 4: 43-47
• 3 Wiley HE, Krivosic V, Gaudric A. et al. Management of Retinal Hemangioblastoma in Von Hippel-Lindau Disease. Retina 2019; 39: 2254-2263
• 4 Latif F, Tory K, Gnarra J. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320
• 5 Lonser RR, Glenn GM, Walther M. et al. von Hippel-Lindau disease. Lancet 2003; 361: 2059-2067
• 6 Karimi S, Arabi A, Shahraki T. et al. Von Hippel-Lindau Disease and the Eye. J Ophthalmic Vis Res 2020; 15: 78-94
• 7 Kreusel KM, Bechrakis NE, Heinichen T. et al. Retinal angiomatosis and von Hippel-Lindau disease. Graefes Arch Clin Exp Ophthalmol 2000; 238: 916-921
• 8 Ruppert MD, Gavin M, Mitchell KT. et al. Ocular Manifestations of von Hippel-Lindau Disease. Cureus 2019; 11: e5319
• 9 Bornfeld N, Kreusel KM. [Capillary hemangioma of the retina in cases of von Hippel-Lindau syndrome. New therapeutic directions]. Ophthalmologe 2007; 104: 114-118
• 10 Gaudric A, Krivosic V, Duguid G. et al. Vitreoretinal surgery for severe retinal capillary hemangiomas in von Hippel-Lindau disease. Ophthalmology 2011; 118: 142-149
• 11 Krivosic V, Kamami-Levy C, Jacob J. et al. Laser Photocoagulation for Peripheral Retinal Capillary Hemangioblastoma in von Hippel-Lindau Disease. Ophthalmol Retina 2017; 1: 59-67
• 12 Sachdeva R, Dadgostar H, Kaiser PK. et al. Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol 2010; 88: e334-e340
• 13 Stattin M, Kralinger M, Haas G. et al. Photodynamic therapy for retinal capillary hemangioblastoma. Can J Ophthalmol 2014; 49: e32-e35
• 14 Magee MA, Kroll AJ, Lou PL. et al. Retinal capillary hemangiomas and von Hippel-Lindau disease. Semin Ophthalmol 2006; 21: 143-150
• 15 Schmidt D, Agostini HT. [Retinal angiomatosis – an ophthalmological challenge]. Klin Monbl Augenheilkd 2007; 224: 905-921
• 16 Biewald E, Schlüter S, Kiefer T. et al. [Tumors and Pseudotumors of the Retina and the Ciliary Epithelium]. Klin Monbl Augenheilkd 2020; 237: 1359-1378
• 17 Kreusel KM, Krause L, Graul-Neumann L. et al. [Family screening in patients with retinal angiomatosis]. Klin Monbl Augenheilkd 2009; 226: 939-943
• 18 Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001; 46: 117-142
• 19 Singh AD, Shields CL, Shields JA. Treatment of retinal capillary hemangioma. Ophthalmology 2002; 109: 1799-1806
• 20 Apple DJ, Goldberg MF, Wyhinny GJ. Argon laser treatment of von Hippel-Lindau retinal angiomaII. Histopathology of treated lesionArch Ophthalmol 1974; 92: 126-130
• 21 Goldberg MF, Duke JR. Von Hippel-Lindau disease. Histopathologic findings in a treated and an untreated eye. Am J Ophthalmol 1968; 66: 693-705
• 22 Russo V, Stella A, Barone A. et al. Ruthenium-106 brachytherapy and intravitreal bevacizumab for retinal capillary hemangioma. Int Ophthalmol 2012; 32: 71-75
• 23 Bergman L, Nilsson B, Lundell G. et al. Ruthenium brachytherapy for uveal melanoma, 1979–2003: survival and functional outcomes in the Swedish population. Ophthalmology 2005; 112: 834-840
• 24 Damato B, Patel I, Campbell IR. et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 385-391
• 25 Barca F, Vicini G, Nicolosi C. et al. Combined brachytherapy and vitreoretinal surgery for a large retinal capillary hemangioma with exudative retinal detachment. Eur J Ophthalmol 2020; DOI: 10.1177/1120672120944013.
• 26 Kreusel KM, Bornfeld N, Lommatzsch A. et al. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 1998; 105: 1386-1392
• 27 Ach T, Thiemeyer D, Hoeh AE. et al. Intravitreal bevacizumab for retinal capillary haemangioma: longterm result. Acta Ophthalmol 2010; 88: e137-e138
• 28 Ziemssen F, Voelker M, Inhoffen W. et al. Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond) 2007; 21: 1125-1126